ALLO-316, an allogeneic CAR T cell therapy targeting CD70, is being evaluated in a Phase 1A/1B study for advanced or metastatic clear cell renal cell carcinoma (ccRCC). The study's design includes a lymphodepletion regimen with cyclophosphamide and fludarabine, with the potential addition of ALLO-647. The ccRCC market is competitive, with established therapies including checkpoint inhibitors and VEGF inhibitors. The successful outcome of this trial could position Allogene Therapeutics favorably against existing treatments, particularly if ALLO-316 demonstrates superior efficacy or safety profiles. Given the unmet need in advanced ccRCC, positive results could lead to significant market opportunities and partnerships.